Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.44 |
| ▸ | CA2 | P00918 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20519996 | 1.00 | CA1 (0.44) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL25939820 | 1.00 | CA1 (0.44) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL8140195 | 0.81 | CHRM2 (0.35) | CA1CA2CA9CA12HSD17B10 | |
| SCHEMBL11364765 | 0.81 | ALDH1A1 (0.38) | CA1CA2CA12MEN1KMT2A | |
| SCHEMBL15927849 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL13868765 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6871204 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL12889180 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL17407788 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL11946139 | 0.79 | CA1 (0.50) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601284-B1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | HOFFMANN LA ROCHE (CH) | 2023-12-27 | — | — | EP | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3601284-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | H. Hoffnabb-La Roche Ag (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183956-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CA1 4815/4885CA2 4661/4885CA9 4504/4885 |
| US-20180282328-A1 | NAPHTHYRIDINES AS INHIBITORS OF HPK1 | NEK1, NEK5, NEK11 | CA1 4815/4885CA2 4661/4885CA9 4504/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | CA1 4815/4885CA2 4661/4885CA9 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.